Big Pharma Deal Making – The Beginning of a New Dawn?

A look at deal trends to gain insight in how behaviours have changed over the last decade.

Pharma is attracted to antibody deals in Oncology

Pharma is attracted to early-stage antibody deals in Oncology. Today, the top ten best-selling antibody therapeutics for cancer have accumulated revenues approaching $200 Billion.  
 

The Upsurgence of Nanotechnology

Nanotechnology to play an increasing role in Nanomedicine.

Industry Insight: Why Size and Timing matter

The CRO sector is a less defined sector of the market where data are much less available, and value more variable.

Reducing Pain for Patients and Dealmakers

Pain management continues to face the dual hurdles of abuse of the most efficacious (opiod based) therapies and the difficulties of developing and commercialising new treatments.

Opportunities in Emerging Markets

Emerging Markets (EMs) are increasingly a key part of the growth strategy of many life science/healthcare companies; the vast majority of healthcare spend growth in pharmaceuticals, medical devices and equipment will be in EMs over the next decade.

Consolidation and Differentiation: Key Drivers of Change in the Global Pharmaceutical Manufacturing Industry

Policy-driven changes in healthcare spending and the growing significance of generic competition are acting in tandem to force pharmaceutical companies to adopt more cost-effective manufacturing strategies resulting in an upsurge in the level of M&A activity in the industry as drugmakers consolidate to reduce costs, diversify product portfolios and expand geographic footprints.

Competitive Deal Activity Profiling (CDAP©)

Deal-making is one of the key strategies employed by pharma companies to fuel growth opportunities. On a spectrum that ranges from intramural organic growth to extramural outright acquisitions, deal-making occupies an intermediate position. One can easily argue that analogous to semi-active investment, this approach should yield highest return for the company as well as its investors on a risk-normalised basis.

Options: Is the Bio/Pharma Industry Becoming More Risk Averse?

In deal-making, options have long been considered a useful vehicle to carry uncertainty through to a point of resolution, or at least to a position of more understandable risk. Many very early stage players prefer the use of options to allow partners an opportunity to uncover value rather than undersell or worse allow good potential to gather dust for lack of resource. Would-be licensees see options as a lower risk / lower cost way of securing assets, seeing the risk reward balance falling in favour of watchful waiting. The pharmaceutical pipeline is a risky environment.

Co-promotion Deals - Panacea or Poison Pill?

The incidence of co-promotion components in biotechnology/pharmaceutical licensing deals for development products has grown steadily since 1996 according to data from PharmaDeals© V4. In 1996 just 6% of licensing deals retained co-promotion rights or options for licensors, to date in 2010 the frequency is double that (12%). We were interested to uncover if these agreements converted into commercial realities and if so did they turn out to be mutual successes for the concerned parties.

Pages